Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography

• Published in: BMC ophthalmology 2020-09, Vol.20 (1), p.382-382, Article 382
• Main Authors: Zhu, Ziyi, Liang, Youling, Yan, Bin, Meng, Zhishang, Long, Kejun, Zhang, Yiwei, Luo, Jing
• Format: Article
• Language: English
• Subjects: Angiography; Automation; Blood flow; Conbercept; Density; Diabetes; Diabetes Mellitus; Diabetic retinopathy; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Edema; Fluorescein Angiography; Humans; Ischemia; Ischemia - drug therapy; Macular Edema - diagnosis; Macular Edema - drug therapy; Macular Edema - etiology; Macular ischemia; Medical imaging; OCT angiography; Ophthalmology; Patients; Perfusion; Ranibizumab; Recombinant Fusion Proteins; Reperfusion; Retinal Vessels - diagnostic imaging; Retinopathy; Tomography, Optical Coherence; Vascular endothelial growth factor; Visual Acuity
• ISSN: 1471-2415; 1471-2415
• DOI: 10.1186/s12886-020-01648-x

Varying degrees of macular ischemia generally occur in diabetic retinopathy (DR). This study aims to evaluate the effect of conbercept with 3+ pro re nata (PRN) on macular perfusion status in patients with diabetic macular edema (DME) and quantitatively assess changes in foveal avascular zone (FAZ) areas and capillary density in macular regions by applying optical coherence tomography angiography (OCTA). Fifty patients were divided into ischemic (n = 31) and non-ischemic (n = 19) groups according to the presence of ischemia on OCTA at baseline. All patients received intravitreal injections of 0.5 mg of conbercept with 3+ PRN principle. The FAZ areas and macular vessel density measured using OCTA were evaluated at baseline, 3 months, and 6 months after treatment in both groups. At months 3 and 6, the FAZ area in the ischemic group changed from 0.510 ± 0.171 mm to 0.441 ± 0.158 mm then to 0.427 ± 0.153 mm (p = 0.003, p = 0.296); in the non-ischemic group, it remained stable (p = 0.269, p = 0.926). The superficial vessel density changed from 41.1 ± 4.1 to 42.5% ± 4.7% then to 42.6% ± 4.6% (p = 0.043, p = 0.812), and the deep vessel density changed from 40.7 ± 4.4 to 42.3% ± 3.6% then to 42.3% ± 4.7% (p = 0.072, p = 0.961) in the ischemic group. In the non-ischemic group, the superficial vessel density changed from 44.8 ± 3.2 to 46.0% ± 3.5% then to 45.7% ± 3.3% (p = 0.108, p = 0.666), whereas the deep vessel density changed from 43.6 ± 3.6 to 43.8% ± 3.2% then to 43.5% ± 4.5% (p = 0.882, p = 0.736). Reperfusion in macular nonperfusion areas was observed. Anti-vascular endothelial growth factor treatment may have a positive effect on macular perfusion status. Furthermore, OCTA had advantages in quantifying and calculating blood flow index in the study of macular perfusion status.